Download PDF
Horm Metab Res 2014; 46(12): 845-853
DOI: 10.1055/s-0034-1384520
Review
© Georg Thieme Verlag KG Stuttgart · New York

Filamin A in Somatostatin and Dopamine Receptor Regulation in Pituitary and the Role of cAMP/PKA Dependent Phosphorylation

E. Peverelli
1   Endocrine Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
,
E. Giardino
1   Endocrine Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
,
E. Vitali
2   Laboratory of Cellular and Molecular Endocrinology, Humanitas Research Center, Rozzano, Italy
,
D. Treppiedi
1   Endocrine Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
,
A. G. Lania
3   Endocrine Unit, IRCCS Humanitas Clinical Institute, Rozzano, University of Milan, Milan, Italy
,
G. Mantovani
1   Endocrine Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
› Author Affiliations
Further Information

Publication History

received 14 March 2014

accepted 18 June 2014

Publication Date:
28 July 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Molecular mechanisms underlying resistance of pituitary tumors to somatostatin (SS) and dopamine (DA) analogues treatment are not completely understood. Resistance has been associated with defective expression of functional somatostatin and dopamine receptors SSTR2, SSTR5, and DRD2, respectively. Recently, a role of cytoskeleton protein filamin A (FLNA) in DRD2 and SSTR receptors expression and signaling in PRL- and GH-secreting tumors, respectively, has been demonstrated, first revealing a link between FLNA expression and responsiveness of pituitary tumors to pharmacological therapy. No molecular events underlying the reduction of FLNA levels in resistant tumors have been so far identified. FLNA can be phosphorylated by PKA on Ser2152, with increased FLNA resistance to cleavage by calpain and conformational changes affecting FLNA regions involved in SSTR2 and DRD2 binding and signal transduction. In this respect, the effect of cAMP/PKA pathway in the regulation of FLNA stability and/or function by modulating its phosphorylation status could assume particular importance in pituitary, where cAMP cascade plays a crucial role in pituitary cell functions and tumorigenesis. This review will discuss the role of FLNA in the regulation of the main GPCRs target of pharmacological treatment of pituitary tumors, that is, SSTR2 and DRD2, focusing on the effects of cAMP/PKA-mediated FLNA phosphorylation on FLNA biological functions.

Key words

cytoskeleton - pituitary tumors - GPCR
 

  • References

  • 1 Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22: 724-763
    CrossrefPubMedGoogle Scholar
  • 2 Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198
    Google Scholar
  • 3 Gueorguiev M, Grossman AB. Pituitary tumors in 2010: a new therapeutic era for pituitary tumors. Nat Rev Endocrinol 2011; 7: 71-73
    Google Scholar
  • 4 Ben-Shlomon A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 2010; 21: 123-133
    CrossrefPubMedGoogle Scholar
  • 5 Peverelli E, Lania AG, Mantovani G, Beck-Peccoz P, Spada A. Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop. Endocrinology 2009; 150: 3169-3176
    Google Scholar
  • 6 Peverelli E, Busnelli M, Vitali E, Giardino E, Galés C, Lania AG, Beck-Peccoz P, Chini B, Mantovani G, Spada A. Specific roles of G(i) protein family members revealed by dissecting SST5 coupling in human pituitary cells. J Cell Sci 2013; 126 (Pt 2) 638-644
    Google Scholar
  • 7 Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Luciani P, Peri A, Mantovani G, Bosari S, Beck-Peccoz P, Spada A, Lania A. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006; 13: 955-962
    Google Scholar
  • 8 Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688-1696
    CrossrefPubMedGoogle Scholar
  • 9 Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002; 13: 451-457
    Google Scholar
  • 10 Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2001; 32: 247-271
    PubMedGoogle Scholar
  • 11 Howlett 1 TA, Willis D, Walker G, Wass JA, Trainer PJ. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf) 2013; 79: 689-699
    Google Scholar
  • 12 Molitch ME. Pharmacologic resistance in prolactinomas patients. Pituitary 2005; 8: 43-52
    CrossrefPubMedGoogle Scholar
  • 13 Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500-509
    CrossrefPubMedGoogle Scholar
  • 14 Passos VQ, Fortes MAHZ, Giannella-Neto D, Bronstein MD. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 2009; 89: 163-170
    CrossrefPubMedGoogle Scholar
  • 15 Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994; 60: 314-322
    CrossrefPubMedGoogle Scholar
  • 16 Friedman E, Adams EF, Höög A, Gejman PV, Carson E, Larsson C, De Marco L, Werner S, Fahlbusch R, Nordenskjöld M. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab 1994; 78: 568-574
    CrossrefPubMedGoogle Scholar
  • 17 Filopanti M., Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S, Peri A, Baglioni S, Fustini MF, Pigliaru F, Monte PD, Borretta G, Ambrosi B, Jaffrain-Rea ML, Gasperi M, Brogioni S, Cannavò S, Mantovani G, Beck-Peccoz P, Lania A, Spada A. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 2008; 8: 357-363
    CrossrefPubMedGoogle Scholar
  • 18 Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with tumor somatostatin receptor status. J Clin Endocrinol Metab 1989; 68: 844-850
    Google Scholar
  • 19 Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting tumors. J Clin Endocrinol Metab 2008; 93: 1203-1210
    Google Scholar
  • 20 Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR. Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008; 158: 295-303
    CrossrefPubMedGoogle Scholar
  • 21 Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ. Correlation of in vitro and in vivo somatotropic tumor responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 2008; 93: 1412-1417
    Google Scholar
  • 22 Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011; 32: 247-271
    Google Scholar
  • 23 Wildemberg LE, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D, Gadelha MR. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 2013; 36: 38-43
    PubMedGoogle Scholar
  • 24 Bertherat J, Chanson P, Dewailly D, Enjalbert A, Jaquet P, Kordon C, Peillon F, Timsit J, Epelbaum J. Resistance to somatostatin (SRIH) analog therapy in acromegaly. Re-evaluation of the correlation between the SRIH receptor status of the pituitary tumor and the in vivo inhibition of GH secretion in response to SRIH analog. Horm Res 1992; 38: 94-99
    CrossrefPubMedGoogle Scholar
  • 25 Bertherat J, Chanson P, Dewailly D, Dupuy M, Jaquet P, Peillon F, Epelbaum J. Somatostatin receptors, adenylate cyclase activity and growth hormone response to octreotide in GH-secreting tumors. J Clin Endocrinol Metab 1993; 7: 1577-1583
    PubMedGoogle Scholar
  • 26 Corbetta S, Ballare E, Mantovani G, Lania AG, Losa M, Di Blasio AM, Spada A. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary tumors: analysis of gene sequence and mRNA expression. Eur J Clin Invest 2001; 31: 208-214
    Google Scholar
  • 27 Petersenn S, Heyens M, Lüdecke DK, Beil FU, Schulte HM. Absence of somatostatin receptor type 2A mutations and gip oncogene in pituitary somatotroph tumors. Clin Endocrinol (Oxf) 2000; 52: 35-42
    Google Scholar
  • 28 Ballarè E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani G, Arosio M, Beck-Peccoz P, Faglia G, Spada A. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001; 86: 3809-3814
    Google Scholar
  • 29 Filopanti M, Ballare E, Lania AG, Bondioni S, Verga U, Locatelli M, Zavanone LM, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary tumors. J Endocrinol Invest 2004; 27: 937-942
    CrossrefPubMedGoogle Scholar
  • 30 Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007; 92: 1592-1599
    Google Scholar
  • 31 Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montañana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Longás AF, Aizpún JIL, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein M-T, Vanbellinghen J-F, Barra GB, Gimenez-Roqueplo A-P, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SPA, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010; 95: E373-E383
    CrossrefPubMedGoogle Scholar
  • 32 Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M, Shapiro SS. Filamins as integrators of cell mechanics and signalling. Nature Rev Mol Cell Biol 2001; 2: 138-145
    CrossrefPubMedGoogle Scholar
  • 33 van der Flier A, Sonnenberg A. Structural and functional aspects of filamins. Biochim Biophys Acta 2001; 1538: 99-117
    CrossrefPubMedGoogle Scholar
  • 34 Hartwig JH, Stossel TP. Isolation and properties of actin, myosin, and a new actin binding protein in rabbit alveolar macrophages. J Biol Chem 1975; 250: 5696-5705
    Google Scholar
  • 35 Feng Y, Walsh CA. The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. Nat Cell Biol 2004; 6: 1034-1038
    CrossrefPubMedGoogle Scholar
  • 36 Fox JW, Lamperti ED, Ekşioğlu YZ, Hong SE, Feng Y, Graham DA, Scheffer IE, Dobyns WB, Hirsch BA, Radtke RA, Berkovic SF, Huttenlocher PR, Walsh CA. Mutations in filamin 1 prevent migration of cerebral cortical neurons in human periventricular heterotopia. Neuron 1998; 21: 1315-1325
    CrossrefPubMedGoogle Scholar
  • 37 Robertson 1 SP, Twigg SR, Sutherland-Smith AJ, Biancalana V, Gorlin RJ, Horn D, Kenwrick SJ, Kim CA, Morava E, Newbury-Ecob R, Orstavik KH, Quarrell OW, Schwartz CE, Shears DJ, Suri M, Kendrick-Jones J, Wilkie AO. Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. Nat Genet 2003; 33: 487-491
    CrossrefPubMedGoogle Scholar
  • 38 Nakamura F, Stossel TP, Hartwig JH. The filamins: organizers of cell structure and function. Cell Adh Migr 2011; 5: 160-169
    Google Scholar
  • 39 Li M, Bermak JC, Wang ZW, Zhou QY. Modulation of dopamine D(2) receptor signaling by actin-binding protein (ABP-280). Mol Pharmacol 2000; 57: 446-452
    PubMedGoogle Scholar
  • 40 Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc Natl Acad Sci USA 2001; 98: 5258-5263
    Google Scholar
  • 41 Lin R, Canfield V, Levenson R. Dominant negative mutants of filamin A block cell surface expression of the D2 dopamine receptor. Pharmacology 2002; 66: 173-181
    Google Scholar
  • 42 Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S, Laws ER, Della Mina P, Villa A, Beck-Peccoz P, Spada A, Lania AG. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab 2012; 97: 967-977
    Google Scholar
  • 43 Scott MG, Pierotti V, Storez H, Lindberg E, Thuret A, Muntaner O, Labbé-Jullié C, Pitcher JA, Marullo S. Cooperative regulation of extracellular signal-regulated kinase activation and cell shape change by filamin A and beta-arrestins. Mol Cell Biol 2006; 26: 3432-3445
    Google Scholar
  • 44 Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, Caron MG. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem 2001; 276: 37409-37414
    CrossrefPubMedGoogle Scholar
  • 45 Zhang M, Breitwieser GE. High affinity interaction with filamin A protects against calcium-sensing receptor degradation. J Biol Chem 2005; 280: 11140-11146
    Google Scholar
  • 46 Seck T, Baron R, Horne WC. Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. J Biol Chem 2003; 278: 10408-10416
    Google Scholar
  • 47 Thelin WR, Chen Y, Gentzsch M, Kreda SM, Sallee JL, Scarlett CO, Borchers CH, Jacobson K, Stutts MJ, Milgram SL. Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. J Clin Invest 2007; 117: 364-374
    Google Scholar
  • 48 Beekman JM, van der Poel CE, van der Linden JA, van den Berg DL, van den Berghe PV, van de Winkel JG, Leusen JH. Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routing. J Immunol 2008; 180: 3938-3945
    Google Scholar
  • 49 Meller E, Puza T, Miller JC, Friedhoff AJ, Schweitzer JW. Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro. J Pharmacol Exp Ther 1991; 257: 668-675
    PubMedGoogle Scholar
  • 50 Najib 1 S, Saint-Laurent N, Estève JP, Schulz S, Boutet-Robinet E, Fourmy D, Lättig J, Mollereau C, Pyronnet S, Susini C, Bousquet C. A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway. Mol Cell Biol 2012; 32: 1004-1016
    Google Scholar
  • 51 Peverelli E, Giardino E, Treppiedi D, Vitali E, Cambiaghi V, Locatelli M, Lasio G, Spada A, Lania A, Mantovani G, Filamin A. (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Endocrinology 2014; en20141063. PMID: 24828612. Epub ahead of print
    PubMedGoogle Scholar
  • 52 Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002; 12: 258-266
    Google Scholar
  • 53 Peverelli E, Mantovani G, Lania AG, Spada A. cAMP in the pituitary: an old messenger for multiple signals. J Mol Endocrinol 2013; 52: R67-R77
    CrossrefPubMedGoogle Scholar
  • 54 Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330: 566-568
    Google Scholar
  • 55 Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340: 692-696
    Google Scholar
  • 56 Lania A, Persani L, Ballaré E, Mantovani S, Losa M, Spada A. Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J Clin Endocrinol Metab 1998; 83: 1624-1628
    CrossrefPubMedGoogle Scholar
  • 57 Persani L, Borgato S, Lania A, Filopanti M, Mantovani G, Conti M, Spada A. Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations. J Clin Endocrinol Metab 2001; 86: 3795-3800
    PubMedGoogle Scholar
  • 58 Mantovani G, Bondioni S, Ferrero S, Gamba B, Ferrante E, Peverelli E, Corbetta S, Locatelli M, Rampini P, Beck-Peccoz P, Spada A, Lania AG. Effect of cyclic adenosine 3',5'-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2005; 90: 6721-6724
    CrossrefPubMedGoogle Scholar
  • 59 Vitali E, Peverelli E, Giardino E, Locatelli M, Lasio GB, Beck-Peccoz P, Spada A, Lania AG, Mantovani G. Cyclic adenosine 3'–5'-monophosphate (cAMP) exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac). Mol Cell Endocrinol 2014; 383: 193-202
    CrossrefPubMedGoogle Scholar
  • 60 Skalhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 2000; 5: D678-D693
    CrossrefPubMedGoogle Scholar
  • 61 Bertherat J, Chanson P, Montminy M. The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 1995; 9: 777-783
    PubMedGoogle Scholar
  • 62 Wu MP, Jay D, Stracher A. Existence of multiple phosphorylated forms of human platelet actin binding protein. Cell Mol Biol Res 1994; 40: 351-357
    PubMedGoogle Scholar
  • 63 Chen M, Stracher A. In situ phosphorylation of platelet actin-binding protein by cAMP-dependent protein kinase stabilizes it against proteolysis by calpain. J Biol Chem 1989; 264: 14282-14289
    PubMedGoogle Scholar
  • 64 Zhang Z, Lawrence J, Stracher A. Phosphorylation of platelet actin binding protein protects against proteolysis by calcium dependent sulfhydryl protease. Biochem Biophys Res Commun 1988; 151: 355-360
    CrossrefPubMedGoogle Scholar
  • 65 Jay D, García EJ, Lara JE, Medina MA, de la Luz Ibarra M. Determination of a cAMP-dependent protein kinase phosphorylation site in the C-terminal region of human endothelial actin-binding protein. Arch Biochem Biophys 2000; 377: 80-84
    CrossrefPubMedGoogle Scholar
  • 66 Hammer A, Rider L, Oladimeji P, Cook L, Li Q, Mattingly RR, Diakonova M. Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolactin through filamin A. Mol Endocrinol 2013; 27: 455-465
    CrossrefPubMedGoogle Scholar
  • 67 Cukier IH, Li Y, Lee JM. Cyclin B1/Cdk1 binds and phosphorylates Filamin A and regulates its ability to cross-link actin. FEBS Lett 2007; 581: 1661-1672
    CrossrefPubMedGoogle Scholar
  • 68 Jay D, Stracher A. Expression in Escherichia coli and phosphorylation with cAMP-dependent protein kinase of the N-terminal region of human endothelial actin-binding protein. Biochem Biophys Res Commun 1994; 202: 764-771
    CrossrefPubMedGoogle Scholar
  • 69 Jay D, García EJ, de la Luz Ibarra M. In situ determination of a PKA phosphorylation site in the C-terminal region of filamin. Mol Cell Biochem 2004; 260: 49-53
    CrossrefPubMedGoogle Scholar
  • 70 Woo MS, Ohta Y, Rabinovitz I, Stossel TP, Blenis J. Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol Cell Biol 2004; 24: 3025-3035
    CrossrefPubMedGoogle Scholar
  • 71 Zhang J, Neal J, Lian G, Shi B, Ferland RJ, Sheen V. Brefeldin A-inhibited guanine exchange factor 2 regulates filamin A phosphorylation and neuronal migration. J Neurosci 2012; 32: 12619-12629
    CrossrefPubMedGoogle Scholar
  • 72 Eto A, Akita Y, Saido TC, Suzuki K, Kawashima S. The role of the calpain-calpastatin system in thyrotropin-releasing hormone-induced selective down-regulation of a protein kinase C isozyme, nPKC epsilon, in rat pituitary GH4C1 cells. J Biol Chem 1995; 270: 25115-25120
    CrossrefPubMedGoogle Scholar
  • 73 Sato-Kusubata K, Yajima Y, Kawashima S. Persistent activation of Gsalpha through limited proteolysis by calpain. Biochem J 2000; 347: 733-740
    CrossrefPubMedGoogle Scholar
  • 74 Ohkawa K, Takada K, Asakura T, Hashizume Y, Okawa Y, Tashiro K, Ueda J, Itoh Y, Hibi N. Calpain inhibitor inhibits secretory granule maturation and secretion of GH. Neuroreport 2000; 11: 4007-4011
    CrossrefPubMedGoogle Scholar
  • 75 Zheng X, Zhou AX, Rouhi P, Uramoto H, Borén J, Cao Y, Pereira T, Akyürek LM, Poellinger L. Hypoxia-induced and calpain-dependent cleavage of filamin A regulates the hypoxic response. Proc Natl Acad Sci USA 2014; 111: 2560-2565
    CrossrefPubMedGoogle Scholar
  • 76 Ozanne DM, Brady ME, Cook S, Gaughan L, Neal DE, Robson CN. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol 2000; 14: 1618-1626
    CrossrefPubMedGoogle Scholar
  • 77 Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci USA 2003; 100: 4562-4567
    CrossrefPubMedGoogle Scholar
  • 78 Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, deVere White RW, Ghosh PM. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene 2000; 26: 6061-6070
    PubMedGoogle Scholar
  • 79 Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med 2010; 207: 2421-2437
    CrossrefPubMedGoogle Scholar
  • 80 García E, Stracher A, Jay D. Calcineurin dephosphorylates the C-terminal region of filamin in an important regulatory site: a possible mechanism for filamin mobilization and cell signaling. Arch Biochem Biophys 2006; 446: 140-150
    CrossrefPubMedGoogle Scholar
  • 81 Calderwood DA, Huttenlocher A, Kiosses WB, Rose DM, Woodside DG, Schwartz MA, Ginsberg MH. Increased filamin binding to beta-integrin cytoplasmic domains inhibits cell migration. Nat Cell Biol 2001; 3: 1060-1068
    CrossrefPubMedGoogle Scholar
  • 82 Loo DT, Kanner SB, Aruffo A. Filamin binds to the cytoplasmic domain of the beta1-integrin. Identification of amino acids responsible for this interaction. J Biol Chem 1998; 273: 23304-23312
    CrossrefPubMedGoogle Scholar
  • 83 Pfaff M, Liu S, Erle DJ, Ginsberg MH. Integrin beta cytoplasmic domains differentially bind to cytoskeletal proteins. J Biol Chem 1998; 273: 6104-6109
    CrossrefPubMedGoogle Scholar
  • 84 Sharma CP, Ezzell RM, Arnaout MA. Direct interaction of filamin (ABP-280) with the beta 2-integrin subunit CD18. J Immunol 1995; 154: 3461-3470
    PubMedGoogle Scholar
  • 85 Kiema T, Lad Y, Jiang P, Oxley CL, Baldassarre M, Wegener KL, Campbell ID, Ylänne J, Calderwood DA. The molecular basis of filamin binding to integrins and competition with talin. Mol Cell 2006; 21: 337-347
    CrossrefPubMedGoogle Scholar
  • 86 Lad Y, Kiema T, Jiang P, Pentikäinen OT, Coles CH, Campbell ID, Calderwood DA, Ylänne J. Structure of three tandem filamin domains reveals auto-inhibition of ligand binding. EMBO J 2007; 26: 3993-4004
    CrossrefPubMedGoogle Scholar
  • 87 Chen HS, Kolahi KS, Mofrad MR. Phosphorylation facilitates the integrin binding of filamin under force. Biophys J 2009; 97: 3095-3104
    CrossrefPubMedGoogle Scholar
  • 88 Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998; 83: 1604-1610
    Google Scholar
  • 89 Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P, Enjalbert A. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 1999; 84: 2759-2765
    PubMedGoogle Scholar